2025
Estimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus
Xu H, Aparicio C, Wats A, Araujo B, Pitzer V, Warren J, Shapiro E, Niccolai L, Weinberger D, Oliveira C. Estimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus. JAMA Network Open 2025, 8: e250380. PMID: 40063022, PMCID: PMC11894488, DOI: 10.1001/jamanetworkopen.2025.0380.Peer-Reviewed Original ResearchConceptsRSV-positive casesCase-control studyRSV infectionLRTI-associated hospitalizationsWeeks postimmunizationLong-acting monoclonal antibodiesTest-negative case-control studyClinical settingRespiratory syncytial virusMultivariate logistic regressionYale New Haven Health SystemRSV diseaseEmergency department dataState immunization registryRSV seasonSyncytial virusNirsevimabPolymerase chain reactionClinical trialsLRTIInfantsPotential confoundersMonoclonal antibodiesBroader outcomesDisease severity
2021
Estimation of the Timing and Intensity of Reemergence of Respiratory Syncytial Virus Following the COVID-19 Pandemic in the US
Zheng Z, Pitzer VE, Shapiro ED, Bont LJ, Weinberger DM. Estimation of the Timing and Intensity of Reemergence of Respiratory Syncytial Virus Following the COVID-19 Pandemic in the US. JAMA Network Open 2021, 4: e2141779. PMID: 34913973, PMCID: PMC8678706, DOI: 10.1001/jamanetworkopen.2021.41779.Peer-Reviewed Original ResearchConceptsRespiratory syncytial virusRSV epidemicsMathematical modelRSV hospitalizationRSV seasonSyncytial virusSummer epidemicsRSV lower respiratory tract infectionLower respiratory tract infectionsCOVID-19 pandemicLarge RSV outbreaksMaternal-derived immunityRespiratory tract infectionsChildren 1 yearYears of ageSARS-CoV-2Simulation modeling studyProphylaxis administrationRSV circulationRSV infectionRSV outbreaksSecondary outcomesTract infectionsPrimary outcomeLeading cause
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply